(Q40580264)

21 September 2017

title

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis (English)

1 reference

21 September 2017

0 references

11

1 reference

21 September 2017

Judith Bellmann-Strobl

4

object named as

Judith Bellmann-Strobl

0 references

Stefan Ehrlich

object named as

Stefan Ehrlich

8

0 references

Klaus-Dieter Wernecke

9

object named as

Klaus-D Wernecke

1 reference

21 September 2017

10

Hans-Dieter Volk

1 reference

21 September 2017

author name string

Klaus-Peter Wandinger

1

1 reference

21 September 2017

Jan D Lünemann

2

1 reference

21 September 2017

Oliver Wengert

3

1 reference

21 September 2017

Orhan Aktas

5

1 reference

21 September 2017

Alexandra Weber

6

1 reference

21 September 2017

Eva Grundström

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

21 September 2017

1 reference

21 September 2017

volume

361

1 reference

21 September 2017

issue

9374

1 reference

21 September 2017

page(s)

2036-2043

1 reference

Immunological aspects of demyelinating diseases

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

CD4+CD28- costimulation-independent T cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Molecular cross-talk between the TRAIL and interferon signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913641-0

7 January 2021

10.1016/S0140-6736(03)13641-0

Identifiers

DOI

1 reference

21 September 2017

1 reference